{
    "2021-04-02": [
        [
            {
                "time": "",
                "original_text": "国信证券----医药生物行业2021年4月投资策略：调整后更均衡，优选内生成长【行业研究】",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "调整",
                        "内生成长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药与健康护理行业月报：年报相继披露 关注高增长公司及A+H股医药投资机会",
                "features": {
                    "keywords": [
                        "医药",
                        "健康护理",
                        "年报",
                        "高增长",
                        "A+H股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "健康护理"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}